David Baker obtained his BSc for studies in Zoology at the University of London in 1983 and obtained his PhD in Immunology/Pathology from the Hunterian Institute within the Royal College of Surgeons of England in 1987. His doctorate studies were concerned with the induction of immune tolerance in delayed hypersensitivities in the skin. During that time worked with the team examining delayed hypersensitivities of the brain and obtained a fellowship to work on multiple sclerosis (MS). He developed novel animal models of relapsing and progressive multiple sclerosis (MS) and has used these for pre-clinical study over a number of years. His research effort has concerned translational neuroscience and has developed a number of approaches used to treat humans and include the induction of antigen-specific immunotolerance, neuroprotection and symptom control. He is part of a team (BartsMS) that facilitated the development of oral cladribine for the treatment of relapsing MS and is part of the team developing treatments for people with advanced MS and helped develop the biology that underpins a variety of investigator led trials. His group uncovered the medicinal benefit of cannabis and compounds within cannabis for the treatment of spasticity in multiple sclerosis. As an alternative approach, he has developed novel Big Conductance Potassium Channel Modulators for control of symptoms in MS and other glutamate hyper-excitation neural conditions. He has taken agents from discovery into phase II human testing. He identified the neuroprotective potential of cannabinoids that has been shown animals and then phase III human studies and the neuroprotective action of sodium channel blockers in two phase II human studies. He also undertook the initial studies that has led to the development of the use of statins for the treatment of MS, currently in phase III trial. Recently, he has uncovered the importance of memory B cells as a major mechanism of action of potentially all disease modifying treatments in relapsing MS. He has developed anti-drug antibody technology that is been used to monitor neutralizing antibody responses and treatment failure in MS and other conditions and has applied this technology to remotely test for COVID-19 in people with MS. Prof Baker, is actively involved in public engagement in science and social media and contributes daily to the MSBlog (www.ms-res.org).
HEADQUARTERS & ADMINISTRATION
53 Rothschild Boulevard
PO Box 68
Tel Aviv, 6100001, Israel
Tel: +972-3-5666166
Fax: +972-3-5666177
office@comtecmed.com
COMTEC SPAIN
Bailen, 95 – 97
pral.1.a – 08009
Barcelona, Spain
Tel: +34-932081145
Fax: +34-934579291
spain-office@comtecmed.com
COMTEC CHINA
Suite 405, Universal Center Building
175 Xiang Yang Road South
Shanghai 200031, China
Tel: +86-21-54660460
Fax: +86-21-54660450
china-office@comtecmed.com
COMTEC USA
415 South Street
POB #3627
Waltham, MA 02453-2700
Tel: +1-914-312-5407
Fax: 972-3-566-6177
usa-office@comtecint.com